Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DAS181 in immunocompromised patients with lower respiratory parainfluenza virus infection
CTR20200160Phase 3Terminated
- Sponsor
- Akeso Biopharma
- Start
- Feb 2020
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of DAS181 in parainfluenza virus infection, sponsored by Akeso Biopharma. Started Feb 2020; status: terminated.
02
Drugs
DAS181
03
Conditions
parainfluenza virus infection
Beyond the preview
Go deeper on CTR20200160.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20200160.